Tagged with B

Belgium Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the increasing trend of personalized medicine, digitalization, big healthcare data, and stakeholder partnerships. Additionally, Van De Sompel also elaborates on Pfizer’s…

Belgium On 16 April 2020, a new Act was adopted by the Belgian parliament to increase the transparency of managed entry agreements (‘MEA’) concluded between pharmaceutical companies and the National Institute for Health and Disability Insurance (‘NIHDI’). MEAs stipulate confidential compensation mechanisms for the Belgian government regarding the publicly-listed price and reimbursement…

China I-Mab Biopharma CFO Jielun Zhu recaps the exciting milestones for the company over the past year since our last interview in May 2019, including most notably their NASDAQ IPO in January 2020, as well as shares some insights on the NASDAQ IPO experience.   Before the IPO, we might have…

Belgium On 8 April 2020, the Belgian federal agency for medicines and health products (‘FAMHP’) adopted a consolidated version of its decision (the ‘Decision’) taking the following urgent measures for certain listed medicines (and raw materials) to avoid medicine shortages during the SARS-CoV-2 pandemic:   Wholesalers, full-line wholesalers and manufacturers are obliged to…

MEA Pierre Fabre’s recently appointed head for Africa, the Middle East and Turkey, Mouloud Boukhachab, outlines his career trajectory, having worked and managed in geographies as diverse as BeNeLux and Morocco. Boukhachab also states his priorities for his new position and his strategy for navigating the ongoing coronavirus pandemic and lockdown…

Belgium Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the country, and the potential of innovative new treatment nodes such as CAR-T.   In the past, we used to collaborate…

Czech Republic Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning itself as the one-stop-shop for both the clinical and analytical aspects of clinical research. He also explains how Quinta Analytica…

Czech Republic PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now.   Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is…

Brazil Below we highlight recent news in Brazilian pharma, including the impact of coronavirus as well as legal and regulatory updates.    Proposal to allow breaking of patents due to Covid-19 A proposal has been made to amend an intellectual property law, adding a clause on allowing compulsory licenses and breaking…

Coronavirus With the global coronavirus pandemic still ongoing and teleworking having become the new normal, pharma executives from across the world are giving us their insights into how they are managing in the age of confinement to ensure continued employee welfare and the safe supply of medications to the patients and…

USA Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market.   In a recent interview with PharmaBoardroom, Biocon’s Commercial Head Global Generics & SVP Marketing Abhijit Zutshi outlined the company’s recipe…

Coronavirus Sophia Ononye-Onyia outlines the key failings in the USA’s response to the coronavirus outbreak and why greater numbers of inter-industry partnerships and increased technological uptake are key to fighting this crisis and reframing the US life sciences industry of the future.   Imagine if we invested billions in epidemiological surveillance…